The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
NICE overturns previous decision on carfilzomib, lenalidomide, and dexamethasone for the treatment of patients with multiple myeloma
The National Institute for Health and Care Excellence (NICE) has changed its stance, and now recommends the combination of carfilzomib, lenalidomide, and dexamethasone for the treatment of patients with multiple myeloma (MM) who have received at least one prior line of therapy.1 This verdict comes after NICE originally published a draft guidance in September 2020 stating it did not recommend the combination due to uncertainty regarding the duration of benefit of treatment.
This decision was overturned after NICE’s independent appraisal committee saw evidence from the ASPIRE clinical trial (NCT01080391), which has shown that a longer progression-free survival and overall survival are seen with this triplet combination compared with dexamethasone and lenalidomide only. In fact, the benefit of therapy was shown to last up to 6 years.2
In addition, the manufacturer has agreed to drop the price of carfilzomib making it an affordable recommendation.
The NICE final appraisal document has been prepared and is currently being reviewed. The expected date of publication, following a 15-day period during which it will be possible to appeal against the document, is 28 April 2021.3
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content